在免疫介导的神经病变中对二利胺胺S-乙转移酶的自身抗体
Yuki Fukami1, Masahiro Iijima1, Haruki H Koike1
1From the Department of Neurology (Y.F., M. Iijima, H.H.K., S. Yagi, S.F., N.M., A.M., M. Iida, S. Yokoi, A.H., Y.I., M.K.), Nagoya University Graduate School of Medicine; Department of Advanced Medicine (M.I.), Nagoya University Hospital; Department of Orthopedic Surgery (J.O., S.I.); and Department of Clinical Research Education (A.H., M.K.), Nagoya University Graduate School of Medicine, Japan.
Neurology(R) neuroimmunology & neuroinflammation
|January 5, 2024
概括
研究人员在患有慢性炎症性脱髓性多神经病变 (CIDP) 的患者中确定了二脂胺 S-乙转移酶 (DLAT) 自体抗体. 这些抗DLAT抗体可以作为传感主导神经病变的生物标志物.
科学领域:
- 神经免疫学 神经免疫学
- 自动抗体发现发现
- 神经病学研究 神经病学研究
背景情况:
- 免疫介导的神经病变,包括CIDP,以自身抗体为特征.
- 识别特定的自身抗体对于诊断和了解疾病机制至关重要.
研究的目的:
- 在CIDP患者中识别与疾病相关的新型自身抗体.
- 调查与已识别的自身抗体相关的临床特征.
主要方法:
- 西方涂抹和质谱法被用来选患者血清对小鼠大脑蛋白.
- 与酶相关的免疫吸收试验 (ELISA),西部涂抹和免疫光试验证实了抗体的反应性.
- 分析了抗体阳性和阴性CIDP患者的临床数据.
主要成果:
- 确定了二利胺S-乙转移酶 (DLAT) 作为一种向抗原.
- 在18%的CIDP患者中检测到抗DLAT抗体,在感官神经病变和MS患者中也检测到.
- 具有抗DLAT抗体的CIDP患者表现出较高的感觉性无氧症,神经疾病和恶性瘤.
结论:
- 在患者血清中证实了对DLAT的反应性,主要在CIDP中.
- DLAT在背部根性质细胞中表达很高.
- 反DLAT抗体可以作为传感主导神经病变的生物标志物.
更多相关视频
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Myasthenia Gravis: Diagnostic Tests
861
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
861


